This persistent burden is why research centers across the country are running hundreds of asthma clinical trials at any given time. These studies range from early safety tests of new molecules to large-scale trials comparing existing treatments head-to-head. What drives this wave of research is a simple reality: standard therapies do not work equally well for everyone.
Take someone with eosinophilic asthma, for example. This subtype often barely responds to high-dose inhaled corticosteroids. For these patients, biologic therapies that target specific inflammatory pathways have opened up new possibilities. One patient who had struggled for years found that after joining a Phase III trial for a biologic targeting eosinophils, she could walk her dog without stopping to catch her breath within a few months. Outcomes like this are becoming more common as precision medicine reshapes asthma care.
Types of Asthma Trials Available Across the U.S.
Clinical trials for asthma generally fall into several categories, and knowing the differences helps patients find the right match. Some studies investigate inhaled medications like triple-combination therapies. Recent approvals have brought triple-therapy inhalers to a broader age range, with Phase III trials showing measurable improvements in lung function compared to dual-combination treatments.
Other trials focus on biologics, which are injectable medications that target specific inflammatory pathways. Several biologics are being studied in various combinations and across different populations. Some ongoing Phase 3b studies are exploring whether patients on certain biologics can safely step down their background maintenance therapy while keeping symptoms controlled. These kinds of studies matter because they address a practical question patients ask constantly: can I eventually use less medication?
Some research programs take a different approach altogether. The PrecISE Network Study, conducted at sites including Mayo Clinic, evaluates precision interventions for severe and exacerbation-prone asthma. Rather than testing a single drug, the study matches patients to treatments based on their specific asthma subtype. This reflects a broader shift toward personalized protocols.
| Trial Type | Example Focus | Typical Duration | Who Might Qualify | Key Consideration |
|---|
| Biologic therapy trials | Injectable biologics targeting inflammatory pathways | 6-24 months | Severe or eosinophilic asthma patients | Requires regular injections and lab monitoring |
| Inhaler studies | Dual and triple-combination therapies | 12-52 weeks | Moderate-to-severe uncontrolled asthma | Often includes placebo comparison arms |
| Step-down trials | Reducing maintenance medication | 6-18 months | Patients stable on biologics | Addresses long-term treatment burden |
| Pediatric studies | Safety and efficacy in ages 6-18 | Varies | Children with severe asthma | Requires parental consent and assent |
| Observational studies | Biomarker and genomic research | Single visit to 2 years | Broad eligibility | No intervention, contributes to understanding disease |
Finding and Evaluating Trial Opportunities
The most reliable starting point is ClinicalTrials.gov, a database maintained by the National Institutes of Health. Users can search by condition, location, and trial phase. Typing "asthma" and filtering for recruiting studies within 50 miles of a zip code yields a list of active trials. Each entry spells out the purpose, eligibility criteria, and contact information for the research team.
Academic medical centers are another major hub. Institutions like the University of Michigan, Brigham and Women's Hospital in Boston, and UC San Diego run multiple asthma trials simultaneously. These sites often have dedicated research coordinators who guide patients through screening.
Private research networks also conduct trials. Many list asthma studies on their websites and offer preliminary screenings. Patients typically undergo a no-cost evaluation visit where the team reviews medical history, performs breathing tests, and determines whether a current trial fits.
Eligibility criteria vary significantly between studies. Most require a physician-confirmed asthma diagnosis and current use of at least one controller medication. Some trials look for patients with specific blood eosinophil counts or a history of exacerbations requiring oral steroids. Others need participants whose lung function falls below a certain threshold, measured by FEV1 (forced expiratory volume in one second). There is no single profile that fits all trials, which is why talking to a research coordinator is often the most efficient first step.
What Participation Actually Looks Like
Compensation structures differ by study length and intensity. Shorter focus groups and surveys related to asthma may provide modest stipends. Longer clinical trials offer more substantial payments to cover time, travel, and the inconvenience of repeated visits. The investigational medication and study-related medical evaluations are provided as part of the trial protocol, so patients are not paying for the treatment itself.
One participant in Tampa enrolled in a clinical trial after his employer changed insurance plans and his medication copays increased. Beyond the financial aspect, he appreciated the thorough monitoring. "I got lung function tests every month. My regular doctor never had time for that," he said.
Patients should ask during screening about the specific visit schedule, any procedures involved, and what happens after the study ends. Some trials include an open-label extension phase where all participants receive the active treatment regardless of their original assignment.
The screening process typically involves a detailed medical history review, spirometry testing, blood work, and sometimes a physical exam. Not everyone who screens will qualify. Researchers set strict criteria to ensure participant safety and data reliability. Being disqualified from one trial does not mean another will turn you away.
Risks, Safeguards, and Informed Consent
Every clinical trial operates under an Institutional Review Board that evaluates the study design for ethical soundness and participant protection. Before enrolling, patients receive an informed consent document that explains the purpose, procedures, potential risks, and alternatives. This is not a contract; participants can withdraw at any time.
Risks vary depending on the intervention. A trial testing a new biologic may involve injection-site reactions, headaches, or, in rare cases, allergic responses. Studies involving inhaled medications could cause temporary throat irritation or cough. The research team monitors all adverse events and adjusts protocols if safety concerns emerge.
Placebo arms deserve honest discussion. Many asthma trials use a randomized, double-blind design where some participants receive the investigational drug and others receive a placebo or standard-of-care comparator. This means you might not get the active treatment. For patients with severe, uncontrolled asthma, this can feel like a gamble. However, most trials allow participants to use their regular rescue inhalers throughout the study, and many protocols include provisions for those whose symptoms worsen.
Steps to Get Started
Reaching out does not commit you to anything. The process begins with a conversation.
A practical starting point: search ClinicalTrials.gov using keywords like "asthma" and your city or state. Review the list for studies marked "recruiting" or "not yet recruiting." Note the NCT number, which is a unique identifier for each trial. Contact the research coordinator listed on the page, either by phone or email. Ask about the screening process, visit frequency, and whether compensation is offered.
Academic centers often have patient portals where you can express interest in multiple studies at once. Private research sites may offer an online pre-screening questionnaire that takes about ten minutes. The American Lung Association also maintains educational resources about clinical trial participation for those who want to learn more before reaching out.
For parents considering pediatric trials, the conversation includes additional layers. Studies evaluating biologic treatments in children with severe eosinophilic asthma require parental consent and the child's assent. Pediatric research coordinators are trained to explain procedures in age-appropriate terms and address family concerns.
Talking to your current pulmonologist or allergist about trial participation is a sensible step. They can assess whether your asthma severity and type align with ongoing research. Some specialists are investigators themselves and may be aware of trials recruiting at their own institutions. Others can help you evaluate whether a particular study's protocol fits your life circumstances, including work schedule, transportation access, and caregiving responsibilities.
研究の知恵